Company Description
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally.
The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs.
In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Country | United States |
| Founded | 2009 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Joshua Riggs |
Contact Details
Address: 15 Cushing Irvine, California 92618 United States | |
| Phone | 949 409 7600 |
| Website | oncocyte.com |
Stock Details
| Ticker Symbol | OCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
| CUSIP Number | 68235C107 |
| ISIN Number | US68235C2061 |
| Employer ID | 27-1041563 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc. |
| Joshua Riggs | President, Chief Executive Officer and Director |
| Andrea Susan James | Chief Financial Officer |
| James Liu | Vice President of Accounting, Treasurer, Controller and Principal Accounting Officer |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Peter Hong | Vice President, General Counsel and Secretary |
| Sandra O'Donald | Senior Vice President of Business Operations |
| Dr. Paul R. Billings FACP, M.D. | Consulting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | ARS | Filing |
| May 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2025 | DEF 14A | Other definitive proxy statements |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 8, 2025 | 424B3 | Prospectus |
| Apr 7, 2025 | EFFECT | Notice of Effectiveness |
| Apr 3, 2025 | UPLOAD | Filing |